Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Receivables - Net (2022 - 2025)

Historic Receivables - Net for Voyager Therapeutics (VYGR) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Voyager Therapeutics' Receivables - Net fell 8003.01% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 8003.01%. This contributed to the annual value of $1.5 million for FY2024, which is 9812.35% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Receivables - Net of $3.2 million as of Q3 2025, which was down 8003.01% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Receivables - Net peaked at $80.1 million during Q4 2023, and registered a low of $837000.0 during Q1 2024.
  • Its 4-year average for Receivables - Net is $14.2 million, with a median of $2.4 million in 2024.
  • As far as peak fluctuations go, Voyager Therapeutics' Receivables - Net tumbled by 9812.35% in 2024, and later soared by 9390.68% in 2025.
  • Voyager Therapeutics' Receivables - Net (Quarter) stood at $10.0 million in 2022, then surged by 701.5% to $80.1 million in 2023, then plummeted by 98.12% to $1.5 million in 2024, then skyrocketed by 111.84% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.